Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer

Unique Biomarkers That May Clarify Treatment Of Triple-Negative Breast Cancer.
In an trouble to pick up the prognosis of patients battling triple-negative breast cancer, scientists have identified a solitary biomarker that may eventually allow some to receive a more targeted treatment. Although less uncommon, triple negative breast cancer is notoriously difficult to treat because receptor targeted therapies don't work.

The disease's honour refers to breast cancers that analysis negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2(HER2), all of which fossil most breast cancer growth. "Triple-negative breast cancers currently require therapeutic targets and are managed with conventional chemotherapy," study author Dr Agnieszka K Witkiewicz, an fellow professor of pathology at Thomas Jefferson University Hospital in Philadelphia, explained in a report release.